SIMULECT (basiliximab)
MONOCLONAL ANTIBODY IMMUNOSUPPRESSIVES · PREVENTION OF KIDNEY TRANSPLANT REJECTION
Novartis Pharmaceuticals
Drug class
Immunosuppress., T-Cell Fxn Inhibiting Monoclonal Antibodies
The phrase "Immunosuppress., T-Cell Fxn Inhibiting Monoclonal Antibodies" is an abbreviated administrative or compendial drug classification heading—most commonly representing "immunosuppressive, T-cell function-inhibiting monoclonal antibodies"—rather than a standard, standalone medical diagnosis or singular clinical entity. Read more about Immunosuppress., T-Cell Fxn Inhibiting Monoclonal Antibodies
3 drugs in this class 3 manufacturers
Drugs in Immunosuppress., T-Cell Fxn Inhibiting Monoclonal Antibodies
NIKTIMVO (axatilimab-csfr)
IMMUNOSUPPRESS., T-CELL FXN INHIBITING MONOCLONAL ANTIBODIES · CHRONIC GRAFT-VERSUS-HOST DISEASE
Incyte Corporation
SIMULECT (basiliximab)
MONOCLONAL ANTIBODY IMMUNOSUPPRESSIVES · PREVENTION OF KIDNEY TRANSPLANT REJECTION
Novartis Pharmaceuticals
Filter & compare in the drug finder →
Opens the drug finder with Immunosuppress., T-Cell Fxn Inhibiting Monoclonal Antibodies preselected. Add indication or manufacturer filters there.
The phrase "Immunosuppress., T-Cell Fxn Inhibiting Monoclonal Antibodies" is an abbreviated administrative or compendial drug classification heading—most commonly representing "immunosuppressive, T-cell function-inhibiting monoclonal antibodies"—rather than a standard, standalone medical diagnosis or singular clinical entity.
Clinically, it refers to engineered monoclonal antibodies designed to induce immunosuppression by selectively targeting and dampening T-lymphocyte activation, proliferation, or downstream signaling.
By blocking key surface receptors, co-stimulatory molecules, or cytokine pathways essential to T-cell-mediated immune responses, these agents prevent destructive cellular immune activity.
Consequently, agents in this category are primarily utilized to prevent or treat allograft rejection in solid organ transplantation and to manage severe, refractory autoimmune disorders.
-
fda.gov
The phrase "Immunosuppress., T-Cell Fxn Inhibiting Monoclonal Antibodies" is an abbreviated administrative or compendial drug classification heading—most commonly representing "immunosuppressive, T-cell function-inhibiting monoclonal antibodies"—rather than a standard, standalone medical diagnosis or singular clinical entity
-
creative-biolabs.com
The phrase "Immunosuppress., T-Cell Fxn Inhibiting Monoclonal Antibodies" is an abbreviated administrative or compendial drug classification heading—most commonly representing "immunosuppressive, T-cell function-inhibiting monoclonal antibodies"—rather than a standard, standalone medical diagnosis or singular clinical entity Clinically, it refers to engineered monoclonal antibodies designed to induce immunosuppression by selectively targeting and dampening T-lymphocyte activation, proliferation,...
-
nih.gov
Clinically, it refers to engineered monoclonal antibodies designed to induce immunosuppression by selectively targeting and dampening T-lymphocyte activation, proliferation, or downstream signaling Consequently, agents in this category are primarily utilized to prevent or treat allograft rejection in solid organ transplantation and to manage severe, refractory autoimmune disorders
-
nih.gov
By blocking key surface receptors, co-stimulatory molecules, or cytokine pathways essential to T-cell-mediated immune responses, these agents prevent destructive cellular immune activity
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.